Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

The general approach should be a combination of rituximab and chemotherapy ... Therapeutic options for relapsed follicular lymphoma include the same traditional regimens used for first-line ...

Rituximab intravenous formulation is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy ...

Rituximab biosimilar is indicated in adults for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy, maintenance therapy is indicated ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Follicular lymphoma is a diverse disease ... The general approach should be a combination of rituximab and chemotherapy, traditionally using alkylating agents, with or without an anthracycline ...

lenalidomide and rituximab in patients with advanced follicular lymphoma. Caimi explained that the findings showed that “1 year of the triplet combination seems to be better than the doublet in ...

Additionally, rituximab had been used in the context of lymphoma with associated cryoglobulinemia. Zaja et al. 15 described their experience of 15 patients with type II MEC (12 with HCV ...

All patients with follicular ... therapy of lymphoma." The study included 86 patients with B-cell lymphomas, 18 of whom received FT596 after conditioning chemotherapy without rituximab, and ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.